MODERN POSSIBILITIES OF THERAPY OF TYPE 2 DIABETES MELLITUS PATIENTS. EFFECTIVENESS AND CARDIOSAFETY OF ALOGLIPTIN FROM THE POINT OF VIEW OF EVIDENCE-BASED MEDICINE
https://doi.org/10.21518/2079-701X-2017-11-156-160
Abstract
According to the IDF (2016) 1 of 11 adult patients suffers from diabetes mellitus (DM). The total number of diabetic patients is 415 million. By 2040, according to analysts of the International Diabetes Federation, the number of the sick increases and the disease will affect 1 in 10 people. It is extremely important to maintain all indicators of carbohydrate metabolism (fasting glucose and postprandial, HbA1c) within the target values. Currently existing recommendations are not obligatory and do not give the strict guidance on the priority use of a group of hypoglycemic drugs and other drugs. The choice of patient-orientated approach, based on the effectiveness and safety of drugs. On the basis of numerous clinical studies have proven the effectiveness and safety of Alogliptin in the treatment of patients with type 2 diabetes.
About the Authors
A. S. Ametov
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof.
Moscow
E. V. Doskina
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine.
Moscow
References
1. http://www.diabetesatlas.org.
2. InternationalDiabetesFederation, 2013. IDFDiabetes Atlas, Sixth edition. www.idf.org/diabetesatlas.
3. http://hsha.ru/wp-content/uploads/2016/11/24_11_Diabet_registr.pdf.
4. Алгоритм специализированной помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова (8 выпуск), М., 2017.
5. Feng J, Zhang Z, Wallace MB et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidylpeptidase 4. J. Med. Chem., 2007, 50: 2297-2300.
6. Сhristopher R, Covington P, Davenport M et al Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of dipeptidylpeptidase 4 inhibitor alogliptin in healthy male subjects. Clin. Ther., 2008, 30: 13-27.
7. American Diabetes Association, Standards of Medical Care in Diabetes – 2015. Diabetes Care, 2015, 38(Suppl. 1): 1-94.
8. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38: 140-9.
9. Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin. Drug Des Devel Ther, 2013, 7: 989-1001.
10. Covington P, Christopher R, Davenport M, Fleck P, Karim A. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-mind, placebocontrolled, multiple-dose study in adult patients with type 2 diabetes. Clin Ther, 2008, 30: 499-512.
11. Ndefo UA, Okoli O, Erowele G. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus. Am J Health Syst Pharm, 2014, 71: 103-109.
12. Jarvis CI, Cabrera A, Charron D. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus. Ann Pharmacother, 2013, 47: 1532-1539.
13. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 008 Group Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract, 2009, 63(1): 46-55.
14. Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q, Alogliptin Study 009 Group Efficacy and safety of the dipeptidyl pepti-dase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin, 2009, 25(10): 2361-2371.
15. Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q, Alogliptin Study 007 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab, 2009, 11(2): 167-176.
16. Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, doubleblind, placebo-controlled trial with an openlabel, long-term extension. Curr Med Res Opin, 2011, 27(Suppl 3): 21-29.
17. White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F. Examination of cardiovascular outcomes with alogliptin versus standard of care in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome. Am Heart J, 2011, 162: 620-626.
18. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB, EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet, 2015, 385: 2067-2076.
19. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q, on behalf of the Alogliptin Study 010 Group. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebocontrolled study. Diabetes Care, 2008, 31(12): 334-356.
20. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. Diabetes Obes Metab, 2014, 16: 1239-1246.
21. Терехова А.Л., Петунина Н.А. Кардиоваскулярная безопасность в терапии сахарного диабета 2-го типа: Фокус на алоглиптин. Медицинский Совет, 2016, 3: 38-46.
22. Недогода С.В., Барыкина И.Н., Саласюк А.С., Смирнова В.О. Фармакоэкономический анализ использования алоглиптина в лечении сахарного диабета 2 типа. Качественная клиническая практика, 2015, 4: 43-52.
23. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 321: 2000, 405-412.
Review
For citations:
Ametov AS, Doskina EV. MODERN POSSIBILITIES OF THERAPY OF TYPE 2 DIABETES MELLITUS PATIENTS. EFFECTIVENESS AND CARDIOSAFETY OF ALOGLIPTIN FROM THE POINT OF VIEW OF EVIDENCE-BASED MEDICINE. Meditsinskiy sovet = Medical Council. 2017;(11):156-160. (In Russ.) https://doi.org/10.21518/2079-701X-2017-11-156-160
Views:
707
Email this article 